NEW YORK (Reuters) - The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug ...